Washington University Paul Calabresi K12 Career Development Award for Clinical Oncology 7. Project Summary / Abstract The goal of the Washington University (WU) Paul Calabresi K12 Career Development Award for Clinical Oncology is to provide didactic coursework, mentored research practicums and specialized career development programs for senior fellows and junior faculty interested in academic careers in oncology. We propose the renewal of this K12 to continue training clinicians from diverse disciplines, including medical oncology, surgical oncology, gynecological oncology, radiation oncology and pediatric oncology, and basic research scientists to design and administer hypothesis-driven pilot/Phase I, Phase II, and Phase III cancer therapeutic clinical trials. We are requesting six slots per year to support senior fellows and junior faculty for two to three year appointments. To enhance our highly successful K12 program, we propose the following:
Aim 1 : Expand the workforce trained to design and execute rigorous oncologic clinical research. We propose to continue to fund six K12 Scholar positions per year at WU over the next five years to support clinician-scientists and non-clinician postdoctoral researchers from diverse disciplines focused on patient oriented cancer research.
Aim 2 : Optimize existing curricula, career development, short-term training, and mentored, hands-on research experiences pertinent to clinical trials and patient oriented research. We will expand upon our current opportunities to offer training in four tracks: Cancer Genomics, Translational Medicine, Patient Centered Outcomes Research, and Cancer Immunology and Cellular Therapy.
Aim 3 : Continue to develop and enhance robust evaluation and tracking of K12 scholars, faculty, mentors, curriculum, and training opportunities. We will monitor progress, demonstrate outcomes, and use short- and long-term results to improve clinical oncology research training. Successful completion of these aims will result in increased numbers of diverse, well-trained investigators who lead hypothesis driven cancer therapeutic clinical trials. By partnering with stakeholders early and throughout the translational enterprise, they will disseminate and implement their research findings in real world practice to advance rapid human health and health care improvements.

Public Health Relevance

Washington University Paul Calabresi K12 Career Development Award for Clinical Oncology 8. Project Narrative Rapid progress in cancer research has led to a number of novel breakthrough therapies recently. Physicians and scientists engaged in patient oriented cancer research need to be trained in emerging and rapidly changing areas of cancer research. We are able to detect changes in the genes inside a cell more accurately now than ever before. Newer drugs that effectively block the function of certain genes can be quite effective in some patients with cancer. Significant advances in immunotherapy offer new hope for patients with a wide variety of cancers. Along with these exciting advances, however, the costs of cancer care are increasing at an alarming rate. To address all these changes, the Washington University Paul Calabresi Oncology K12 Program aims to train a new generation of basic and clinical investigators in the areas of genetics/genomics, translational medicine, patient centered outcomes research, and cancer immunology and cellular therapy in order to advance healthcare delivery and outcomes for cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
2K12CA167540-06
Application #
9296912
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Damico, Mark W
Project Start
2012-04-16
Project End
2022-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
6
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Waqar, Saiama N; Waqar, Sadaf H; Trinkaus, Kathryn et al. (2018) Brain Metastases at Presentation in Patients With Non-Small Cell Lung Cancer. Am J Clin Oncol 41:36-40
Mian, Hira S; Wildes, Tanya M; Fiala, Mark A (2018) Development of a Medicare Health Outcomes Survey Deficit-Accumulation Frailty Index and Its Application to Older Patients With Newly Diagnosed Multiple Myeloma. JCO Clin Cancer Inform 2018:
Christopher, Matthew J; Petti, Allegra A; Rettig, Michael P et al. (2018) Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. N Engl J Med 379:2330-2341
Zhou, Amy; Holmes, Holly M; Hurria, Arti et al. (2018) An Analysis of the Inclusion of Medications Considered Potentially Inappropriate in Older Adults in Chemotherapy Templates for Hematologic Malignancies: One Recommendation for All? Drugs Aging 35:459-465
Wildes, Tanya M; Maggiore, Ronald J; Tew, William P et al. (2018) Factors associated with falls in older adults with cancer: a validated model from the Cancer and Aging Research Group. Support Care Cancer 26:3563-3570
Waqar, Saiama N; Boehmer, Leigh; Morgensztern, Daniel et al. (2018) Immunogenicity of Influenza Vaccination in Patients With Cancer. Am J Clin Oncol 41:248-253
Warner, Wayne A; Spencer, David H; Trissal, Maria et al. (2018) Expression profiling of snoRNAs in normal hematopoiesis and AML. Blood Adv 2:151-163
Waqar, Saiama N; Samson, Pamela P; Robinson, Cliff G et al. (2018) Non-small-cell Lung Cancer With Brain Metastasis at Presentation. Clin Lung Cancer 19:e373-e379
Fakhri, Bita; Fiala, Mark A; Tuchman, Sascha A et al. (2018) Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. Clin Lymphoma Myeloma Leuk 18:219-224
Cherian, Mathew A; Olson, Sydney; Sundaramoorthi, Hemalatha et al. (2018) An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia. J Biol Chem 293:6844-6858

Showing the most recent 10 out of 92 publications